Shuttle Pharmaceuticals Discloses Auditor Change in 8-K Filing
Shuttle Pharmaceuticals Holdings, Inc. (SEC file no. 0001757499) filed an 8-K on November 6, 2026, disclosing a change in certifying accountant under Item 4.01. The filing requires disclosure of prior auditor’s opinion type, disagreements, and any internal control deficiencies — though reasons remain unstated.
51CFO view：Auditor changes are major red flags for IPO-bound firms: CFOs must manage seamless handover between firms, ensure full transfer of 3-year audit workpapers, and fully disclose rationale in the S-1 (e.g., 'scope misalignment' not 'disagreement'). Internal control deficiencies trigger immediate SOX 404(b) remediation to avoid IPO delays.
Shuttle Pharmaceuticals Holdings, Inc. (SEC file no. 0001757499) filed an 8-K on November 6, 2026, disclosing a change in certifying accountant under Item 4.01. The filing requires disclosure of prior auditor’s opinion type, disagreements, and any internal control deficiencies — though reasons remain unstated.
Source：SEC EDGAR · 8-K 重大事项公告
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →
Who builds SOX 404 internal controls?
The first-year audit requirement after listing, and when to start.
Read →